FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DArecca James						2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]								(Ch	eck all applic	ationship of Reporting k all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	ner	
(Last) 125 SUM	(Fi MMER STR	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/02/2022									X Officer (give title below) EVP, Chief Financial Officer					
(Street) BOSTON		tate)	02110 (Zip)	Domi	-									Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1 Title of 9	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature																			
Date						Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)						Securitie Beneficia	Securities Beneficially Owned Following		: Direct r Indirect str. 4)	of Indirect Beneficial Ownership (Instr. 4)		
								Cod	de V		Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(111301. 4)		
Common	Stock			05/02	2/202	022		A			5,902	5,902 ⁽¹⁾ A		(2)	5,902			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, To Security or Exercise (Month/Day/Year) if any C			Transa Code (I	ansaction of ode (Instr. Derivative			Expiration Date of Se (Month/Day/Year) Unde Deriv				of Sec Under Deriva	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable		xpiration ate	Title	N O	umber					
Non- qualified Stock Option (Right to Buy)	\$50.83	05/02/2022			A		13,828		(3)	05	5/02/2029	Comm		3,828	\$0	13,82	8	D	

Explanation of Responses:

- 1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- 2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- 3. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

/s/ Thomas V. Powers, attorney-05/04/2022 in-fact for Mr. D'Arecca

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.